If Teva's mystery drug isn't Lipitor, could it be ...?
This article was originally published in Scrip
Comments made by executives of Teva Pharmaceutical Industries during the third-quarter results call this week have been picked apart by analysts and other observers who claim to have deduced that the company is planning to launch a generic version of Pfizer's Lipitor (atorvastatin) in the US in the next month or so, despite the fact that the 6-month period of generic exclusivity in the US rests with Ranbaxy.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.